Navigation Links
Isis Pharmaceuticals to Present at Thomas Weisel Partners' Healthcare Conference 2009
Date:9/3/2009

CARLSBAD, Calif., Sept. 3 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the 2009 Thomas Weisel Partners Healthcare Conference on Wednesday, September 9, 2009, at 11:30 a.m. ET at the Boston Four Seasons Hotel.

A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, www.isispharm.com. A replay of the presentation will be available on the Isis Web site within 48 hours and will be archived for a limited time.

About Isis Pharmaceuticals, Inc.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 19 drugs in development. Isis' drug development programs are focused on treating cardiovascular, metabolic and severe neurodegenerative diseases and cancer. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Isis and Alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA therapeutics. Isis also has made significant innovations beyond human therapeutics resulting in products that other companies, including Abbott, are commercializing. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,600 issued patents worldwide. Additional information about Isis is available at www.isispharm.com.


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Endo Pharmaceuticals Gives Update on Regulatory Status of Testosterone Undecanoate for Men with Hypogonadism
2. DUSA Pharmaceuticals to Present at the Rodman & Renshaw 11th Annual Healthcare Conference
3. Transdel Pharmaceuticals to Present at Thomas Weisel Partners Healthcare Conference
4. MAP Pharmaceuticals to Present at Upcoming Healthcare and Scientific Conferences
5. Lexicon Pharmaceuticals to Present at the Thomas Weisel Partners Healthcare Conference
6. EPIX Pharmaceuticals, Inc. Announces the P2Y2 Gastrointestinal Early Development Candidate Program Will Be Part of the Intellectual Property Offered For Sale at the September 30, 2009 Auction
7. Cumberland Pharmaceuticals to Present at UBS Global Life Sciences Conference in New York on September 21, 2009
8. Endo Pharmaceuticals to Present at Thomas Weisel Partners Healthcare Conference 2009
9. Keryx Biopharmaceuticals, Inc. To Present at the Rodman & Renshaw Annual Global Investment Conference and To Hold Investor/Analyst Day
10. Peregrine Pharmaceuticals Adds Noted Oncologist Dr. Bruce Chabner as Clinical Advisor to Support Advancement of Its Clinical Programs
11. Watson Pharmaceuticals Receives FDA Approval for Generic PLAN B(R) for Over-the-Counter Use
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... Albuquerque, NM (PRWEB) , ... December 06, 2016 ... ... awarded JumpStart Autism Center with an Award of Distinction, recognizing the organization as ... needs providers that excel in the areas of clinical quality, staff satisfaction and ...
(Date:12/6/2016)... ... December 06, 2016 , ... Experimentation involving human stem cells ... due to its potential for revolutionizing human disease treatment. There are multiple HSC ... stem cells (hiPSCs). , Both platforms have distinct advantages and disadvantages, but ...
(Date:12/6/2016)... , ... December 06, 2016 , ... ... one-stop portal for all the knowledge resources, including white papers, guides, handbooks, case ... more. , To access more than 9,000 documents, webinars and videos available ...
(Date:12/6/2016)... , ... December 06, 2016 , ... 'Tis the season ... daily routines. That means it's also the season when eating healthy, staying active, and ... diabetes) on schedule is harder to do. , "Shopping trips, parties and family ...
(Date:12/6/2016)... ... 06, 2016 , ... Specialty Technical Publishers (STP) and Specialty ... Consortium (IAPC) EHS audit protocol for Great Britain . Leading companies around ... EHS regulatory obligations and rapidly collect, share, archive, and export audit findings in ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... , December 5, 2016 According to a new report ... by Application - Global Opportunity Analysis and Industry Forecast, 2014 - 2022", the ... to reach $5,255 million by 2022, growing at a CAGR of 6.4% from ... than four-fifths share. Continue Reading ... ...
(Date:12/5/2016)... and PUNE, India , December 5, ... by Allied Market Research, titled, "Global Cancer Biomarkers Market - ... of cancer biomarkers market is projected to reach $15,737 million ... of 13.3% from 2016 to 2022. Omic technologies segment accounted ... and is expected to maintain its dominance during the forecast ...
(Date:12/5/2016)... Dec. 5, 2016   TrainerMD , the first HIPAA compliant ... new collaboration with Styku . Styku, a ... Kinect hardware to provide users world-class, real-time 3D body scanning and ... the means to see, hear and feel their health like never ... , , ...
Breaking Medicine Technology: